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Alzheimer’s disease (AD) is the most common type of dementia and has no effective
therapies. Previous studies showed that bone morphogenetic protein 9 (BMP9), an
important factor in the differentiation and phenotype maintenance of cholinergic neurons,
ameliorated the cholinergic defects resulting from amyloid deposition. These findings
suggest that BMP9 has potential as a therapeutic agent for AD. However, the effects
of BMP9 on cognitive function in AD and its underlying mechanisms remain elusive. In
the present study, BMP9 was delivered intranasally to 7-month-old APP/PS1 mice for
4 weeks. Our data showed that intranasal BMP9 administration significantly improved
the spatial and associative learning and memory of APP/PS1 mice. We also found that
intranasal BMP9 administration significantly reduced the amyloid β (Aβ) plaques overall,
inhibited tau hyperphosphorylation, and suppressed neuroinflammation in the transgenic
mouse brain. Furthermore, intranasal BMP9 administration significantly promoted the
expression of low-density lipoprotein receptor-related protein 1 (LRP1), an important
membrane receptor involved in the clearance of amyloid β via the blood-brain barrier
(BBB), and elevated the phosphorylation levels of glycogen synthase kinase-3β (Ser9),
which is considered the main kinase involved in tau hyperphosphorylation. Our results
suggest that BMP9 may be a promising candidate for treating AD by targeting multiple
key pathways in the disease pathogenesis.
Keywords: bone morphogenetic protein 9, Alzheimer’s disease, amyloid β, tau, neuroinflammation, low-density
lipoprotein receptor-related protein 1, glycogen synthase kinase-3β
INTRODUCTION
Alzheimer’s disease (AD), the most common type of dementia among the elderly, is characterized
clinically by progressive memory loss and other cognitive dysfunctions and pathologically by
extracellular amyloid β (Aβ) plaques, intracellular neurofibrillary tangles (NFTs) composed of
hyperphosphorylated tau, together with the loss of neurons and synapses (Citron, 2010). Aβ is
generated from the sequential proteolytic cleavage of amyloid precursor protein (APP) through
β- and γ-secretase (Hardy and Selkoe, 2002). A great amount of evidence suggests that the
extracellular accumulation, aggregation, and deposition of Aβ play pivotal roles in the pathogenesis
of AD by triggering subsequent pathological events, such as tau hyperphosphorylation,
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neuroinflammation, oxidative stress, neuronal loss and synaptic
degeneration. These secondary pathological events then
accelerate the progression of AD (Hardy and Higgins, 1992;
Tanzi and Bertram, 2005; Bettens et al., 2013). Unfortunately,
all the drugs targeting Aβ through immunotherapy or secretase
inhibitors have failed to improve cognitive function in AD
patients (Doody et al., 2014; Salloway et al., 2014; Lovestone
et al., 2015). Very recently, tau aggregation inhibitors also
showed no substantial effects against memory decline in AD
patients (Gauthier et al., 2016). These failed clinical trials suggest
that targeting amyloid plaques or tau aggregation alone might
be insufficient to halt the progression of dementia in AD. Thus,
multi-target drugs may be the alternative treatments for AD.
Bone morphogenetic protein 9 (BMP9), also known as
growth differentiation factor 2, belongs to the transforming
growth factor beta (TGF-β) superfamily (Brown et al.,
2005). BMP9 signal transduction begins when it binds to
transmembrane serine/threonine kinase receptors, which
induce the phosphorylation of Smad1, Smad5 and Smad8.
Then, the phosphorylated Smads form a complex with Smad4,
which translocates into the nucleus, binds to Smad-responsive
elements, and eventually induces the transcription of target genes
(Bandyopadhyay et al., 2013; Zhong and Zou, 2014). BMP9 has
been shown to regulate multiple biological functions, including
cartilage formation (Hu et al., 2013), angiogenesis (Levet et al.,
2013), and glucose and lipid metabolism (Caperuto et al., 2008)
via both autocrine and paracrine pathways (Miller et al., 2000).
Recently, BMP9 was determined to be highly expressed in the
basal forebrain, where cholinergic neurons are mainly located
(López-Coviella et al., 2000). Subsequent evidence revealed
that BMP9 was critical for the differentiation, maturation, and
phenotype maintenance of cholinergic neurons (López-Coviella
et al., 2000, 2005; Schnitzler et al., 2010), suggesting that
BMP9 may exert beneficial effects in the treatment of diseases
associated with the profound degeneration of cholinergic
systems, such as AD (Whitehouse et al., 1982; Grothe et al.,
2010).
Indeed, the intracerebroventricular infusion of BMP9 has
recently been demonstrated to counteract the cholinergic defects
and reduce amyloidosis in APP.PS1/CHGFP mice (Burke
et al., 2013). However, whether BMP9 can ameliorate the
cognitive deficits in AD, as well as the hyperphosphorylation
of tau and neuroinflammation, remains elusive. Here, we
demonstrate that a 4-week intranasal BMP9 treatment reduced
both the amyloid plaque load and Aβ levels, inhibited
tau hyperphosphorylation, suppressed neuroinflammation, and
finally reversed the cognitive impairments in APPswe/PSEN1dE9
(APP/PS1) mice.
MATERIALS AND METHODS
Animals
APPswe/PSEN1dE9 mice with a C57BL/6 background were
obtained from The Jackson Laboratory (strain name, B6C3-Tg
(APPswe, PSEN1dE9) 85Dbo/J; stock number 004462)
(Jankowsky et al., 2004). Heterozygous males were bred
with wild-type (WT) C57BL/6 females purchased from the
Shanghai Research Center for Model Organisms (China).
Offspring were genotyped using PCR with primers specific for
the APP sequence (Forward: GAATTCCGACATGACTCAGG;
Reverse: GTTCTGCTGCATCTTGGACA). Mice not expressing
the transgene were adopted as the littermate WT controls.
Seven-month-old males were used in all the studies. The animals
were housed in groups with free access to water and chow
in a temperature-controlled (20–22◦C) vivarium and were
maintained on a 12-h light/dark cycle. This study and all mouse
care and experimental procedures were approved by the Medical
Experimental Animal Administrative Committee of Fudan
University.
BMP9 Administration
The intranasal route allows small molecules to rapidly enter the
cerebrospinal fluid, followed by subsequent distribution to the
brain and spinal cord (Scafidi et al., 2014). Recombinant human
BMP9 (R&D Biosciences) was prepared at a concentration of
20 µg/mL using sterile 4 mM HCl containing 0.2% bovine
serum albumin (BSA). Each mouse was held ventral side up,
and a small, modified 27-French catheter was inserted into
either naris. Then, no more than 4 µL of BMP9 was slowly
administered, for a total of 50 ng/(g.d). The mouse was held for
1–2 min to ensure absorption. BMP9 was administered daily for
30 days. Mice in the control group were administered an equal
amount of vehicle (4 mM HCl containing 0.2% BSA; n = 12 per
group).
Morris Water Maze
The Morris water maze test was performed as previously
described (McClean et al., 2011). Briefly, the acquisition training
paradigm for the Morris water maze consisted of four trials
(60-s maximum; 30-min intervals) performed each day for
five consecutive days. Escape latency, path length and velocity
were recorded during the training days. The probe test was
performed 24 h after the last acquisition trial. The platform was
removed, and the mice were introduced into the water from
a novel entry point. The mice were allowed to swim freely
for 1 min while the number of platform crossings and the
time spent in the target quadrant were recorded (n = 12 per
group).
Contextual Fear Conditioning
The contextual fear conditioning test was performed following
previously described methods (Li et al., 2014). In brief, on the
day of training, animals were allowed to explore a conditioning
chamber for 120 s before the delivery of a 30-s acoustic
conditioned stimulus (CS; white noise, 80 dB, 5000 Hz). During
the last 2 s of the CS, a shock unconditioned stimulus (US;
0.6 mA) was applied to the grid floor. A total of 3 CS–US
pairs with 30-s intervals were presented to each animal. The
fear learning test was performed 24 h after training. To evaluate
contextual fear learning, animals were returned to the training
chamber, and freezing behavior was scored for 3 min. Cued
fear learning was assessed 4 h after contextual testing by
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placing animals in a novel environment, i.e., one with a novel
odor, lighting, cage floor and visual cues. After 120 s of free
exploration, the animals were exposed to the exact same three CS
tones with 30-s intervals without the shock. Freezing responses
were recorded. Data are represented as percentages of freezing
behavior (n = 12 per group).
Tissue Preparation for
Immunofluorescence
Mice were deeply anesthetized with pentobarbital sodium
(50 mg/kg, intraperitoneally [i.p.]), and then transcardially
perfused with saline and a 4% (w/v) paraformaldehyde fixative
in phosphate-buffered saline (PBS, pH 7.4). Whole brains were
removed and post-fixed overnight at 4◦C, and then immersed
consecutively in 20% and 30% sucrose solutions before being
embedded in O.T.C. Coronal brain sections (30 µm) were
prepared using a Vibratome (Leica). The sections were stored at
4◦C in a cryoprotectant (30% glycerol, 30% ethylene glycol and
40% PBS) until processing (n = 6 per group).
Immunofluorescence
Free-floating sections were rinsed and blocked with 10% (w/v)
normal donkey serum in Tris-buffered saline (TBS) for 1 h
at room temperature. Then, the sections were incubated with
primary antibodies for 48 h at 4◦C. The following primary
antibodies were used: mouse anti-Aβ monoclonal antibody
(6E10; Covance, 1:500); mouse anti-phospho-tau (ser202,
Thr205; AT-8; Thermo Fisher, 1:200); rabbit anti-ionized
calcium-binding adapter molecule 1 (Iba1) antibody (Abcam,
1:200); and rabbit anti-glial fibrillary acidic protein (GFAP)
antibody (Abcam, 1:200). The sections were then rinsed with
TBS and incubated for 2 h at room temperature with the
respective secondary antibodies, Alexa Fluor-555-conjugated
donkey anti-mouse IgG (Jackson ImmunoResearch, 1:200),
Alexa Fluor-488-conjugated donkey anti-mouse IgG (Jackson
ImmunoResearch, 1:200) or Alexa Fluor-488-conjugated donkey
anti-rabbit IgG (Jackson ImmunoResearch, 1:200). After a final
rinse in TBS, the sections were mounted on chrome-alum
gelatin-coated slides, air-dried and covered with glycerol (diluted
in PBS, 1:1, v/v). Staining was visualized using fluorescence
microscopy (Leica, Japan; n = 6 per group).
Thioflavin-S Staining
Brain sections were incubated with a 0.5% thioflavin-S
solution dissolved in distilled water containing 50% ethanol
for 20 min and differentiated in 50% ethanol three times.
Fluorescence imaging was performed using an Olympus
fluorescence microscope (Olympus Corporation, Japan). To
quantify the plaque load, the areas of 10 sections of the cortex and
hippocampus in each group were calculated (n = 6 per group).
Aβ ELISA
Aβ ELISA was performed as previously described (Gontier
et al., 2015). In brief, the cortical and hippocampal tissues
were thoroughly homogenized in TBS containing a protease
inhibitor cocktail (Roche). The homogenates were then mixed
1:1 with 0.4% diethylamine (DEA), sonicated and centrifuged
at 13,000 g for 30 min at 4◦C. The supernatants were collected
for the quantification of soluble Aβ. Meanwhile, the pellets were
homogenized in 70% formic acid (FA). After sonication and
centrifugation, the supernatants were collected for the analysis
of insoluble Aβ. The Aβ concentrations were detected using
human Aβ40 and Aβ42 ELISA kits (Invitrogen) following the
manufacturer’s instructions. The normalized amounts of Aβ
were expressed as pmol/mg of protein (n = 6 per group).
BMP9 ELISA
The mice were sacrificed by decapitation, and the cortex
and hippocampus were dissected on ice. Tissue samples were
frozen immediately on dry ice and stored at −80◦C until
analysis. Tissues were homogenized in TBS containing a
protease inhibitor cocktail (Roche). After centrifugation, the
supernatants were collected. BMP9 levels were measured using a
BMP9 ELISA kit according to the manufacturer’s protocol (R&D
Biosciences). The absorbance at 450 nm was measured with
a spectrophotometer. The normalized amounts of BMP9 were
expressed as pg/100 mg of protein (n = 6 per group).
Western Blot Analysis
Brain tissues were dissected and homogenized in RIPA buffer
containing a cocktail of protease and phosphatase inhibitors, as
previously described (Wang et al., 2016). Protein concentrations
were determined using a bicinchoninic acid protein assay
kit (Pierce). Equal amounts of total protein (20 µg) were
electrophoresed on 10% SDS-PAGE gels, and then transferred
onto nitrocellulose membranes (Bio-Rad). After the membranes
were blocked with 5% BSA in TBST for 1 h at room temperature,
the membranes were incubated with primary antibodies
overnight at 4◦C. The following primary antibodies were used:
mouse anti-Aβ monoclonal antibody (6E10; Covance, 1:1000);
rabbit anti-beta-secretase 1 (BACE1) antibody (Abcam, 1:1000);
rabbit anti-insulin-degrading enzyme (IDE) antibody (Abcam,
1:1000); rabbit anti-neprilysin (NEP) antibody (Abcam, 1:5000);
rabbit anti-receptor for advanced glycation endproducts (RAGE)
antibody (Abcam, 1:2000); rabbit anti-low-density lipoprotein
receptor-related protein 1 (LRP1) antibody (Abcam, 1:5000);
rabbit anti-phospho-tau (Thr181; CST, 1:1000); rabbit anti-
phospho-tau (Ser 396; CST, 1:1000); rabbit anti-phospho-tau
(Ser 199; CST, 1:1000); rabbit anti-phospho-tau (Ser 356;
CST, 1:1000); mouse anti-tau (Tau-5; Abcam, 1:1000); rabbit
anti-phospho-GSK3β (Ser9; CST, 1:1000); rabbit anti-GSK3β
(CST, 1:1000); rabbit anti-phospho-GSK3α (CST, 1:1000);
rabbit anti-GSK3α (CST, 1:1000); rabbit anti-cyclin-dependent
kinase 5 (CDK5; CST, 1:1000); rabbit anti-protein phosphatase
2 (PP2)A-C (CST, 1:1000); rabbit anti-phospho-PP2A-C (Y307;
R&D Biosciences 1:1000), rabbit anti-demethylated PP2A-C
(D-PP2A-C; CST, 1:1000), rabbit anti-PP2B (CST, 1:1000),
rabbit anti-phospho-extracellular signal-regulated kinase 1 and 2
(ERK1/2; Abcam, 1:1000); rabbit anti-ERK1/2 (Abcam, 1:1000);
rabbit anti-phospho-p38 mitogen-activated protein kinase
(MAPK; Abcam, 1:1000); rabbit anti-p38 MAPK (Abcam,
1:1000); rabbit anti-phospho-Smad1/5/8 (CST, 1:1000); rabbit
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anti-Smad1/5/8 (CST, 1:1000); rabbit anti-Smad4 (Abcam,
1:5000); and mouse anti-GAPDH antibody (Abcam, 1:10,000).
After being washed in TBST, themembranes were incubated with
the respective IRDye 800CW-labeled or IRDye 680CW-labeled
secondary antibodies (1:1000) for 1 h at room temperature.
After a final wash in TBST, the signals were detected with an
Odyssey Infrared Imaging System (LICOR Bioscience, Lincoln,
NE). ImageJ (NIH) was utilized for protein band densitometry
(n = 6 per group).
Quantitative Real-time PCR
Total RNA was isolated from brain tissues using a total RNA kit
(Omega) according to the manufacturer’s instructions. Reverse
transcription was performed using a PrimeScriptTM II 1st
Strand cDNA Synthesis kit (Takara), and the reaction mix was
subjected to quantitative real-time PCR using a SYBRr Premix
Ex TaqTM II (Tli RNaseH Plus) kit (Takara) to detect the
corresponding mouse interleukin 1 beta (IL-1β), IL-6, tumor
necrosis factor alpha (TNF-α), IL-4, IL-10, TGF-β, monocyte
chemotactic protein 1 (MCP-1), and macrophage inflammatory
protein 1 alpha (MIP-1α) transcription levels. A set of β-actin
primers was used as an internal control for each specific gene
amplification. The real-time value for each sample was compared
using the comparative (CT) method, where the amount of target
RNA (2−4CT) was normalized to the endogenous actin reference
(4CT; Schmittgen and Livak, 2008; n = 6 per group). The primers
used for quantitative real-time PCR are listed in Table 1.
Statistical Analysis
All reported experiments were performed in triplicate and
conducted at least three times. Data are reported as the
mean ± standard deviation (SD). Statistical analyses were
performed using GraphPad Prism software (version 5, GraphPad
Software). Student’s t test was performed for statistical analyses
between two groups. ANOVA followed by Bonferroni’s post hoc
test was used when three or more groups were compared.
Statistical significance was defined as p< 0.05.
TABLE 1 | Primers used for quantitative real-time PCR.
Gene Direction Sequence
TNF-α F 5′-CCCTCACACTCAGATCATCTTCT-3′
R 5′-GCTACGACGTGGGCTACAG-3′
Il-1β F 5′-TAGTCCTTCCTACCCCAATTTCC-3′
R 5′-TTGGTCCTTAGCCACTCCTTC-3′
IL-6 F 5′-GCAACTGTTCCTGAACTCAACT-3′
R 5′-ATCTTTTGGGGTCCGTCAACT-3′
IL-4 F 5′-GGTCTCAACCCCCAGCTAGT-3′
R 5′-GCCGATGATCTCTCTCAAGTGAT-3′
IL-10 F 5′-TGGCCACACTTGAGAGCTGC-3′
R 5′-TTCAGGGATGAAGCGGCTGG-3′
TGF-β F 5′-CTCCCGTGGCTTCTAGTGC-3′
R 5′-GCCTTAGTTTGGACAGGATCTG-3′
MIP-1α F 5′-TTCTCTGTACCATGACACTCTGC-3′
R 5′-CGTGGAATCTTCCGGCTGTAG-3′
MCP-1 F 5′-TAAAAACCTGGATCGGAACCAA-3′
R 5′-GCATTAGCTTCAGATTTACGGGT-3′
β-Actin F 5′-GGCTGTATTCCCCTCCATCG-3′
R 5′-CCAGTTGGTAACAATGCCATGT-3′
RESULTS
BMP9 Was Successfully Delivered into the
Brain via the Intranasal Pathway
Given that BMP9 is unlikely to cross the blood-brain
barrier (BBB), the intranasal pathway was used in the
present study to investigate the therapeutic effects of
BMP9 in a transgenic model of AD. We first measured
the concentration of BMP9 in the cortex and hippocampus
using a BMP9 ELISA kit. As shown in Figure 1, the level of
BMP9 was significantly increased in the brains of BMP9-treated
APP/PS1 mice (cortex, 113.5 ± 12.5 pg/100 mg; hippocampus,
121.0 ± 16.3 pg/100 mg) compared with the vehicle-
treated group (cortex, 23.3 ± 7.8 pg/100 mg; hippocampus,
24.5± 5.9 pg/100 mg; ANOVA, p< 0.05, n = 12), indicating that
BMP9 was successfully delivered into the brain via the intranasal
pathway.
BMP9 Improved Cognitive Function in
APP/PS1 Mice
To investigate whether BMP9 could ameliorate AD-associated
learning and memory deficits, cognitive function was first
tested using the Morris water maze. During acquisition, WT
mice showed a day-to-day decrease in escape latency, whereas
APP/PS1 mice displayed a significantly longer escape latency
(Figures 2A,B, ANOVA, p < 0.05, n = 12). In addition, the
path length to find the platform was longer for APP/PS1 mice
than for WT mice (Figure 2C, ANOVA, p < 0.05, n = 12).
During the probe trial test, APP/PS1 mice crossed the platform
less often and spent less time within the target quadrant than
did WT mice (Figures 2D,E, ANOVA, p < 0.05, n = 12).
Strikingly, the impaired spatial learning and memory exhibited
by APP/PS1 mice were rescued by treatment with BMP9, as
demonstrated by the BMP9-treated APP/PS1 mice showing a
reduced escape latency, shortened path length to the platform,
FIGURE 1 | Bone morphogenetic protein 9 (BMP9) was successfully
delivered into the brain via the intranasal pathway. BMP9 concentrations
in the cortex and hippocampus were measured using a BMP9 ELISA kit.
Values are represented as the mean ± SD. ANOVA followed by Bonferroni’s
post hoc test. ∗p < 0.05, n = 12.
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FIGURE 2 | BMP9 treatment rescued impaired spatial and associative learning and memory in APP/PS1 mice. (A) Typical swimming traces during the
acquisition test showing the effects of BMP9 on the spatial memory of APP/PS1 mice. (B) Escape latency in the Morris water maze plotted against the training days.
(C) Average distance to find the platform. (D) Times crossing the target sites after retrieval of the platform. (E) Percentage of time spent in the target quadrant during
a 60-sec probe trial. (F,G) Mean freezing behavior in the contextual (F) and cued (G) fear conditioning tests. Values are represented as the mean ± SD. ANOVA
followed by Bonferroni’s post hoc test. ∗p < 0.05, n = 12.
increased platform crossing, and increased target quadrant
occupation, which were all comparable to those displayed byWT
mice (Figures 2B–E, ANOVA, p< 0.05, n = 12).
We next investigated the effects of BMP9 on APP/PS1 mouse
associative learning and memory using a standard conditioned
fear memory paradigm (Fu et al., 2016). For both contextual
and cued fear conditioning, APP/PS1 mice exhibited
decreased freezing behavior than the WT mice, indicating
that the APP/PS1 mice had an impaired associative memory
(Figures 2F,G, ANOVA, p < 0.05, n = 12). However, the
intranasal BMP9 treatment restored the impaired associative
memory of APP/PS1 mice, as indicated by augmented freezing
responses in both the contextual and cued fear conditioning tests
(Figures 2F,G, ANOVA, p < 0.05, n = 12). These data indicate
that BMP9 can improve the cognitive function of APP/PS1 mice.
BMP9 Reduced Aβ Deposition and Levels
in APP/PS1 Mice
To investigate the effects of BMP9 on Aβ deposition, we
performed thioflavin-S staining for mature amyloid plaques and
Aβ immunostaining (6E10) for total amyloid plaques. As shown
in Figures 3A,B, BMP9-treated APP/PS1 mice exhibited lower
areas of thioflavin-S-stained plaques than did vehicle-treated
mice (ANOVA, p < 0.05, n = 6). Immunofluorescence Aβ brain
deposition studies confirmed this observation, showing that the
Aβ immunopositive areas occupied by 6E10 immunoreactions
were significantly lower in BMP9-treated APP/PS1 mice than in
vehicle-treated mice (Figures 3C,D, ANOVA, p < 0.05, n = 6).
To extend on the amyloid plaque results, the levels of different
Aβ isoforms in the cortex and hippocampus were measured by
ELISA. BMP9-treated APP/PS1 mice showed a marked decrease
in the brain levels of both soluble (DEA extractable) and insoluble
(FA extractable) Aβ40 and Aβ42 compared with vehicle-treated
mice (Figures 3E–H, ANOVA, p< 0.05, n = 6).
To investigate the potential mechanisms responsible for the
effect of BMP9 on Aβ, we examined the metabolism of its
precursor, the Aβ precursor protein (APP), using western blot
analyses. Consistent with the immunofluorescence analysis, the
level of Aβ in the hippocampus of BMP9-treated APP/PS1
mice was significantly lower than that in vehicle-treated
mice. However, the levels of full-length APP (APPfl), secreted
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FIGURE 3 | BMP9 treatment diminished amyloid plaque pathology and Aβ levels in APP/PS1 mice. (A,B) Brain sections of the cortex and hippocampus
were stained with thioflavin-S, and the proportions of Aβ-positive area were calculated. Bar = 100 µm. (C,D) The Aβ plaques in the cortex and hippocampus were
estimated after immunofluorescence staining with Aβ antibodies (6E10), and the proportions of positive area were calculated. Bar = 100 µm. (E–H) The levels of
soluble and insoluble Aβ were measured using ELISA. (I) Representative western blots of APPfl, sAPPα, C-terminal fragment beta (CTFβ), Aβ, BACE1, IDE, NEP,
RAGE, lipoprotein receptor-related protein 1 (LRP1), and GAPDH in the hippocampus homogenates from APP/PS1 mice treated with vehicle or BMP9.
(J) Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel. Values are represented as the mean ± SD. Student’s t test or
ANOVA followed by Bonferroni’s post hoc test. ∗p < 0.05, n = 6.
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APP alpha (sAPPα), C-terminal fragment beta (CTFβ), and
BACE1 remained unchanged (Figures 3I,J, ANOVA, p > 0.05,
n = 6). We also analyzed two of the major proteases involved
in Aβ degradation, IDE and NEP, and found that the levels
of these proteins did not differ between the BMP9-treated
and vehicle-treated groups (Figures 3I,J, ANOVA, p > 0.05,
n = 6). We further analyzed the two transporters mediating the
transportation of Aβ, RAGE and LRP1, and observed that the
level of LRP1, which mediates the efflux of Aβ, was significantly
increased in BMP9-treated APP/PS1 mice compared with
vehicle-treated mice (Figures 3I,J, ANOVA, p < 0.05, n = 6). In
contrast, the level of RAGE, which is involved in the influx of Aβ,
remained unchanged (Figures 3I,J). These results suggest that
BMP9 attenuates the Aβ burden in the brains of APP/PS1 mice,
probably by promoting the LRP1-mediated efflux of Aβ.
BMP9 Inhibited Tau Hyperphosphorylation
in APP/PS1 Mice
Tangles composed of hyperphosphorylated tau are another
important pathological characteristic of AD. To investigate
whether BMP9 could affect tau pathology, coronal brain sections
of the cortex and hippocampus were stained with antibodies
against phospho-tau (Ser202, Thr205; AT-8). As shown in
Figures 4A,B, the proportions of areas with AT-8-positive
neurons in the cortex and hippocampus were significantly lower
in BMP9-treated APP/PS1 mice than in vehicle-treated mice
(ANOVA, p< 0.05, n = 6). Consistently, the western blot analysis
further showed that tau phosphorylation at multiple sites,
including Ser396, Ser199, Ser356 and Thr181, was significantly
diminished in the brains of BMP9-treated APP/PS1 mice
(Figures 4C,D, ANOVA, p< 0.05, n = 6).
To study the mechanisms underlying the effects of
BMP9 on tau phosphorylation, we next examined kinases
and phosphatases that are considered major regulators of its
posttranslational modifications (Dolan and Johnson, 2010). As
shown in Figures 4E,F, compared with vehicle-treated mice, the
brains of BMP9-treated mice showed a significantly increased
level of phosphorylated GSK3β (Ser9; Student’s t test, p < 0.05,
n = 6). In contrast, no differences were found among the levels
of total or phosphorylated GSK3α, CDK5, PP2A-C, pPP2A-C
(Y307), D-PP2A-C, or PP2B (Student’s t test, p > 0.05, n = 6).
Since GSK3β phosphorylation at Ser9 leads to the inhibition
of its activity, our findings suggest that BMP9 administration
suppresses tau hyperphosphorylation, probably by deactivating
GSK3β.
BMP9 Attenuated Neuroinflammation in
APP/PS1 Mice
Neuroinflammation characterized by the activation of
microglia and astrocytes is an important component of
AD (Heneka et al., 2015). As such, we examined whether
intranasal BMP9 administration could inhibit glial activation in
APP/PS1 mice. Coronal sections of the cortex and hippocampus
were stainedwith an antibody against Iba-1, which is indicative of
pronounced microglia activation. We found that BMP9-treated
APP/PS1 mice displayed less intense immunohistochemical
Iba-1 labeling in the cortex and hippocampus than did vehicle-
treated mice (Figures 5A,B, Student’s t test, p < 0.05, n = 6),
suggesting that BMP9 exerted an inhibitive effect on microglial
activation. Similar to microglia, astrocytes are also strongly
activated during the progression of AD and closely associated
with disease pathology (Birch, 2014). Compared with the
vehicle-treated mice, BMP9-treated APP/PS1 mice exhibited a
30–40% decrease in the proportions of GFAP-immunoreactive
areas in the cortex and hippocampus (Figures 5C,D, Student’s
t test, p < 0.05, n = 6), indicating that BMP9 also suppresses
astrocyte activation. Activated microglia and astrocytes secrete
inflammatory cytokines and chemokines, causing neuronal
and synaptic dysfunction. We found that the transcription
levels of proinflammatory cytokines (IL-1β, IL-6 and TNF-α)
and chemokines (MCP-1 and MIP-1α) were significantly
decreased in BMP9-treated APP/PS1 mice (Figure 5E,
ANOVA, p < 0.05, n = 6). In contrast, the transcripts
of anti-inflammatory cytokines (IL-4, IL-10 and TGF-β)
were profoundly increased in BMP9-treated APP/PS1 mice
(Figure 5E, ANOVA, p < 0.05, n = 6). Together, these results
indicate that intranasal BMP9 administration attenuates
neuroinflammation in APP/PS1 mice.
BMP9 Activated Smad-Dependent
Signaling in APP/PS1 Mice
BMP9, acting on a tetrameric receptor complex, transduces
signals mainly via Smad-dependent signaling pathways
(Wu et al., 2016). Recently, crosstalk has also been found
between Smad and MAPK signaling pathways. To investigate
which pathway mediated the beneficial effects of BMP9 in
APP/PS1 mice, the protein levels of pSmad1/5/8, Smad1/5/8,
Smad4, pERK1/2, ERK1/2, pp38MAPK and p38MAPK in the
hippocampal homogenates were detected by western blot. As
shown in Figure 6, intranasal BMP9 administration significantly
increased the levels of pSmad1/5/8 (Student’s t test, p < 0.05,
n = 6), while having no effects on the phosphorylation of
ERK1/2 or p38 MAPK (Student’s t test, p > 0.05, n = 6).
These data suggest that BMP9 exerts beneficial effects against
AD-like pathological and memory deficits, likely via canonical
Smad-dependent signaling pathways.
DISCUSSION
In the present study, we found that the intranasal administration
of BMP9 significantly reduced the amyloid plaque load and Aβ
levels in the brains of APP/PS1 mice, probably by promoting
the efflux of Aβ mediated by LRP1. In addition, BMP9 inhibited
tau hyperphosphorylation in the cortex and hippocampus,
possibly by the deactivation of GSK3β. Further, BMP9 attenuated
the activation of astrocytes and microglia. More importantly,
BMP9 rescued the impaired spatial and associative learning and
memory of APP/PS1 mice. Together, our results suggest that
BMP9 ameliorates cognitive impairments in AD by targeting
multiple key pathways in the disease pathogenesis.
The BBB prevents foreign materials, particularly large and
charged materials, from entering the brain. During past decades,
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FIGURE 4 | BMP9 treatment attenuated tau phosphorylation in APP/PS1 mice. (A) Brain sections of the cortex and hippocampus were stained with
anti-phospho-tau (ser202, Thr205; AT-8). (B) The proportions of AT-8-positive area were calculated. Bar = 100 µm. (C) Representative western blots of
phosphorylated tau at residues T181, S356, S396, and S199, as well as those of total tau and GAPDH in the hippocampus homogenates from APP/PS1 mice
treated with vehicle or BMP9. (D) Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel. (E) Representative western blots of
pGSK3α, GSK3α, pGSK3β, GSK3β, cyclin-dependent kinase 5 (CDK5), PP2A-C, pPP2A-C (Y307), demethylated PP2A-C (D-PP2A-C), PP2A-B and GAPDH in the
hippocampus homogenates from APP/PS1 mice treated with vehicle or BMP9. (F) Densitometric analyses of the immunoreactivities to the antibodies shown in the
previous panel. Values are represented as the mean ± SD. Student’s t test or ANOVA followed by Bonferroni’s post hoc test. ∗p < 0.05, n = 6.
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FIGURE 5 | BMP9 treatment reduced neuroinflammation in APP/PS1 mice. (A) Brain sections of the cortex and hippocampus were stained with anti-Iba1.
Bar = 100 µm. (B) The proportions of Iba1-positive area were calculated. (C) Brain sections of the cortex and hippocampus were stained with anti-glial fibrillary
acidic protein (GFAP). Bar = 100 µm. (D) The proportions of GFAP-positive area were calculated. (E) The transcripts of cytokines and chemokines in the brains of
APP/PS1 mice treated with vehicle or BMP9 were measured by quantitative RT-PCR. Values are represented as the mean ± SD. Student’s t test or ANOVA followed
by Bonferroni’s post hoc test. ∗p < 0.05, n = 6.
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FIGURE 6 | BMP9 acted via a canonical Smad-dependent signaling pathway in APP/PS1 mice. (A) Representative western blots of pSmad1/5/8,
Smad1/5/8, Smad4, pERK1/2, ERK1/2, pp38 mitogen-activated protein kinase (MAPK), p38 MAPK and GAPDH in the hippocampus homogenates from
APP/PS1 mice treated with vehicle or BMP9. (B) Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel. Values are
represented as the mean ± SD. Student’s t test. ∗p < 0.05, n = 6.
the intranasal pathway has been developed as a novel and
non-invasive method for delivering therapeutic substances
directly to the central nervous system (Chapman et al.,
2013). Various studies have confirmed the safety of a variety
of intranasal compounds, including insulin, leptin, oxytocin,
insulin-like growth factor 1 and even stem cells (De Rosa et al.,
2005; Benedict et al., 2007; Chapman et al., 2013). Nonetheless,
the possible adverse effects of intranasal drugs on the local
nasal mucosa should not be neglected. Given that BMP9 is
unlikely to cross the BBB, the intranasal pathway was used in the
present study to investigate the therapeutic effects of BMP9 in
a transgenic mouse model of AD. We found a significantly
increased level of BMP9 in both the cortex and hippocampus
of BMP9-treated APP/PS1 mice compared with vehicle-treated
APP/PS1 mice, indicating that BMP9 was successfully delivered
to the brain. Strikingly, we further found that the impaired
spatial memory function assessed by the Morris water maze was
significantly reversed by a 4-week intranasal BMP9 treatment.
Consistently, the associative memory function evaluated by the
fear conditioning test in APP/PS1 mice was also profoundly
ameliorated by BMP9. To the best of our knowledge, we are the
first to show that intranasal BMP9 administration can ameliorate
cognitive impairments in AD transgenic mice.
In line with the behavioral studies, we observed that the
brains of BMP9-treated APP/PS1 mice had significantly less
Aβ deposition than did vehicle-treated mice. This observation
is consistent with a previous report showing that a 7-day
intracerebroventricular infusion of BMP9 reduced the number
of Aβ42-positive amyloid plaques in the hippocampus and
cerebral cortex of 5- and 10-month-old APP.PS1/CHGFP mice
(Burke et al., 2013). The decreased Aβ plaque burden was
further confirmed by the findings that both the soluble and
insoluble Aβ1–40 and Aβ1–42 fractions were much lower in
the brains of BMP9-treated APP/PS1 mice. In contrast to our
observations, Burke et al. (2013) found no significant effects of
BMP9 on soluble Aβ40 and Aβ42 levels. This discrepancy may be
partially derived from the different BMP9 treatment periods. The
administration of BMP9 lasted for 4 weeks in our study, while it
only lasted 7 days in the study by Burke et al. (2013). BMP9 was
suggested to slow the aggregation and deposition of Aβ in a rapid
manner; however, the clearance of Aβ from the brain was much
slower (Mellott et al., 2014).
To unravel the possible mechanisms underlying the beneficial
effect of BMP9 on Aβ plaques and burden, the APP proteolytic,
Aβ catalytic, and Aβ transportation pathways were investigated.
The protein levels of total APP, sAPPα, CTFβ and BACE
remained unchanged, indicating that BMP9 does not affect APP
processing. Meanwhile, BMP9 did not affect the catalysis of
Aβ, as demonstrated by the similar protein levels of IDE and
NEP, which are involved in the degradation of Aβ. Strikingly,
compared to vehicle-treated APP/PS1 mice, an increased
LRP1 protein level was found in the brains of BMP9-treatedmice,
while the level of RAGE, which mediates the influx of Aβ, was
unaffected. LRP1 is ubiquitously expressed in various cells in
the brain, including neurons, glial cells, and brain endothelial
cells. The conditional knockout of LRP1 in the neurons of
APP/PS1 mice resulted in exacerbated amyloid pathology in
the brain (Kanekiyo et al., 2013). Studies have also shown
that LRP1 in astrocytes and microglia controlled the uptake
of extracellular Aβ and further mediated glial activation (LaDu
et al., 2000; Laporte et al., 2004). Brain endothelial cell-specific
LRP1 deletion in AD transgenic mice led to elevated levels of
soluble brain Aβ and amyloid plaques, resulting in aggravated
cognitive deficits (Kanekiyo et al., 2012; Storck et al., 2016).
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These data suggest that LRP1 in the brain plays a critical role
in the clearance of Aβ. Therefore, the significantly increased
level of LRP1 in BMP9-treated APP/PS1 mice suggests that
BMP9 reduces Aβ accumulation and plaque burden, probably
by promoting the LRP1-mediated efflux of Aβ. Further studies
using LRP1 knockout APP/PS1mice are warranted to thoroughly
clarify the role of LRP1 in the BMP9-induced clearance of Aβ.
The intracellular aggregation of hyperphosphorylated
tau in the form of NFTs is another pathological hallmark
of AD (Ballatore et al., 2007; Small and Duff, 2008).
Hyperphosphorylated tau detaches from microtubules and
accumulates in paired helical filaments, leading to axonal
dysfunction and synaptic failure (Stoothoff and Johnson,
2005; Spillantini and Goedert, 2013). Furthermore, tau
hyperphosphorylation is more closely correlated with the
degree of dementia in AD than are amyloid plaques (Braak
and Braak, 1991; Ballatore et al., 2007). Significant cognitive
impairment was consistently found in different transgenic
mouse models of tauopathy (Polydoro et al., 2009; Sydow
et al., 2011; Van der Jeugd et al., 2012). These observations
led to the hypothesis that tau pathology could be a novel
target for AD treatment (Himmelstein et al., 2012). In the
present study, compared to vehicle-treated mice, BMP9-treated
APP/PS1 mice had a significantly decreased brain level of
hyperphosphorylated tau, as demonstrated by the decreased
immunofluorescence intensity of AT8 in both the cortex and
hippocampus. These observations were further confirmed by
the findings that intranasal BMP9 significantly suppressed the
hyperphosphorylation of tau at several sites, including Ser396,
Ser199, Ser356, and Thr181. These data strongly indicate that
BMP9 could also repress the hyperphosphorylation of tau in
APP/PS1 mice.
The phosphorylation status of tau is controlled by the
activities of various kinases and phosphatases. Kinases involved
in the phosphorylation of tau include GSK3β, CDK5, Fyn,
and microtubule affinity-regulating kinases. Of these, GSK3β
and CDK5 are considered the main tau kinases responsible
for phosphorylating the majority of epitopes present in paired
helical filament tau. In addition, tau is dephosphorylated mainly
by PP2A and to a lesser extent by PP2B, PP1, and PP5
(Planel et al., 2001; Dolan and Johnson, 2010). Therefore,
the present study focused on the activated forms of GSK3β,
CDK5, and PP2A. We found that BMP9 selectively increased
the phosphorylation of GSK3β at Ser9, while having no effects
on CDK5 or PP2A. In accordance with our observations,
BMP9 has also been reported to suppress the activity of
GSK3β in preadipocytes (Liu et al., 2014). GSK3β, initially
identified as a kinase involved in glycogen metabolism, is now
considered the major physiological and pathological tau kinase
(Rayasam et al., 2009; Hernandez et al., 2013). GSK3β activation
has induced tauopathy-related phenotypes in mouse models
(Terwel et al., 2008; Crespo-Biel et al., 2014), and GSK3β
inhibitors have exhibited beneficial effects against tauopathy
and neurodegeneration in tau transgenic mice (Uno et al.,
2009; Martinez et al., 2011). These findings suggest that GSK3β
inhibitors may have therapeutic potential in the treatment of AD.
Given that BMP9 significantly upregulated the phosphorylation
of pGSK3β at Ser9, which led to its inactivation, we posit
that BMP9 suppresses tau hyperphosphorylation in the brains
of APP/PS1 mice by inhibiting the activity of GSK3β. Studies
using specific GSK3β activators are needed to further confirm
the role of GSK3β in the inhibitive effect of BMP9 on tau
hyperphosphorylation.
Neuroinflammation, manifested by the activation of
microglia and astrocytes, is another important component
of AD pathology and contributes to disease progression (Heneka
et al., 2015; Calsolaro and Edison, 2016). In AD, microglia
have been implicated in the generation of chronic neurotoxic
inflammation around amyloid plaques, while being unable
to clear the plaques effectively (Pimplikar, 2014; Pasqualetti
et al., 2015). In addition, activated microglia secrete a wide
range of cytokines and other proinflammatory factors, which
contributes to neurodegeneration and exacerbate inflammatory
reactions by recruiting and stimulating astrocytes (Rubio-Perez
and Morillas-Ruiz, 2012; Ransohoff, 2016). More importantly,
non-steroidal anti-inflammatory drugs (NSAIDs) dramatically
reduced the risk for AD, delayed disease onset, ameliorated
symptomatic severity, and slowed cognitive decline (In ’t
Veld et al., 1998; Arvanitakis et al., 2008; Breitner et al.,
2009; Lehrer, 2014). Thus, targeting neuroinflammation has
been proposed as a novel AD treatment strategy (Pimplikar,
2014; Bronzuoli et al., 2016). Noticeably, we showed here
that intranasal BMP9 administration significantly suppressed
the activation of microglia and astrocytes. In contrast with
our results, Burke et al. (2013) demonstrated that BMP9 did
not affect hippocampal gliosis in APP.PS1/CHGP mice. The
reasons leading to this discrepancy are complex. First, the
BMP9 treatment period was longer in our study. Second,
astrocyte activation was not evaluated by immunofluorescence
in Burke’s study. Third, the state of microglial activation was
not assessed in their study. In line with our immunofluorescence
findings, we further demonstrated that BMP9 significantly
decreased the levels of proinflammatory cytokines (IL-1β, IL-6,
TNF-α) and chemokines (MCP-1, MIP-1α), while increasing
the levels of anti-inflammatory cytokines (IL-4, IL-10, TGF-β).
This switch from proinflammatory to anti-inflammatory
cytokine secretion supports the notion that BMP9 could
suppress neuroinflammation in APP/PS1 mice. Together,
our observations indicate that intranasally administered
BMP9 also acts as an efficient inhibitor of neuroinflammation in
APP/PS1 mice.
Like other members of the TGF-β superfamily,
BMP9 functions via the Smad1/5/8 signaling pathway
(Bandyopadhyay et al., 2013; Zhong and Zou, 2014). The
activation of this Smad signaling pathway was necessary not
only for BMP9-mediated osteogenic stem cell differentiation
(Wang et al., 2013; Chen et al., 2016) but was also essential for
BMP9-induced human endothelial cell quiescence (Rostama
et al., 2015). Furthermore, the Smad signaling pathway may
be responsible for the induction of the cholinergic phenotype
by BMP9 in the basal forebrain (López-Coviella et al., 2006).
In agreement with these studies, we demonstrated in the
present study that intranasal BMP9 administration significantly
promoted the phosphorylation of Smad1/5/8 in the hippocampus
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of APP/PS1 mice. Meanwhile, the MAPK signaling pathways,
which are also suggested to be involved in the beneficial effects
of BMP9, were unaffected, as demonstrated by the unchanged
pERK and pp38MAPK levels. These results indicate that
BMP9 exerts a beneficial effect against cognitive impairment via
a Smad-dependent signaling pathway in APP/PS1 mice.
Increasing evidence shows that there is an interaction between
BMP9 and the Wnt/β-catenin signaling pathway (Liu et al.,
2014). We should bear in mind that activation of the canonical
Wnt pathway would lead to the phosphorylation and subsequent
deactivation of GSK3β (Wu and Pan, 2010). Interestingly, we
found in the present study that BMP9 significantly increased
the levels of phosphorylated GSK3β in APP/PS1 mice. We
hypothesize that crosstalk between the Smad and Wnt/β-catenin
signaling pathways may be responsible for the deactivation of
GSK3β by BMP9 in APP/PS1 mice. Further studies using specific
protein kinase inhibitors or siRNAs are warranted to verify this
hypothesis.
In conclusion, we uncovered an application of BMP9 for
the treatment of AD in a transgenic model by targeting
multiple key pathways, including Aβ clearance mediated by
LRP1, tau hyperphosphorylation mediated by GSK3β, and
neuroinflammation. These data suggest that BMP9 holds
potential as a promising candidate for the treatment of AD.
Clinical trials are warranted to verify the efficacy of BMP9 in AD
patients.
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